Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets - PubMed (original) (raw)

. 2014 Nov;21(12):3827-34.

doi: 10.1245/s10434-014-3828-x. Epub 2014 Jun 3.

Darrell R Borger, Yuhree Kim, David Cosgrove, Aslam Ejaz, Sorin Alexandrescu, Ryan Thomas Groeschl, Vikram Deshpande, James M Lindberg, Cristina Ferrone, Christine Sempoux, Thomas Yau, Ronnie Poon, Irinel Popescu, Todd W Bauer, T Clark Gamblin, Jean Francois Gigot, Robert A Anders, Timothy M Pawlik

Affiliations

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets

Andrew X Zhu et al. Ann Surg Oncol. 2014 Nov.

Abstract

Background: The molecular alterations that drive tumorigenesis in intrahepatic cholangiocarcinoma (ICC) remain poorly defined. We sought to determine the incidence and prognostic significance of mutations associated with ICC among patients undergoing surgical resection.

Methods: Multiplexed mutational profiling was performed using nucleic acids that were extracted from 200 resected ICC tumor specimens from 7 centers. The frequency of mutations was ascertained and the effect on outcome was determined.

Results: The majority of patients (61.5 %) had no genetic mutation identified. Among the 77 patients (38.5 %) with a genetic mutation, only a small number of gene mutations were identified with a frequency of >5 %: IDH1 (15.5 %) and KRAS (8.6 %). Other genetic mutations were identified in very low frequency: BRAF (4.9 %), IDH2 (4.5 %), PIK3CA (4.3 %), NRAS (3.1 %), TP53 (2.5 %), MAP2K1 (1.9 %), CTNNB1 (0.6 %), and PTEN (0.6 %). Among patients with an IDH1-mutant tumor, approximately 7 % were associated with a concurrent PIK3CA gene mutation or a mutation in MAP2K1 (4 %). No concurrent mutations in IDH1 and KRAS were noted. Compared with ICC tumors that had no identified mutation, IDH1-mutant tumors were more often bilateral (odds ratio 2.75), while KRAS-mutant tumors were more likely to be associated with R1 margin (odds ratio 6.51) (both P < 0.05). Although clinicopathological features such as tumor number and nodal status were associated with survival, no specific mutation was associated with prognosis.

Conclusions: Most somatic mutations in resected ICC tissue are found at low frequency, supporting a need for broad-based mutational profiling in these patients. IDH1 and KRAS were the most common mutations noted. Although certain mutations were associated with ICC clinicopathological features, mutational status did not seemingly affect long-term prognosis.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE The authors declare no conflict of interest.

Figures

FIG. 1

FIG. 1

A multiplexed mutational profiling platform was used to identify cancer gene mutations in diagnostic cholangiocarcinoma tissue. The frequency of cancer gene mutations identified are expressed as a percentage of all tumors that were tested. Mutational profiling was performed on 162 patient samples. An additional 38 samples were included for IDH1 and IDH2 analysis only (n = 200)

References

    1. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–477. - PubMed
    1. Poultsides GA, Zhu AX, Choti MA, et al. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90:817–837. - PubMed
    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281. - PubMed
    1. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531–3540. - PMC - PubMed
    1. Sia D, Tovar V, Moeini A, et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013;32:4861–4870. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources